A clinical risk score to predict 3-, 5- and 10-year survival in patients undergoing surgery for Dukes B colorectal cancer
- PMID: 20808311
- PMCID: PMC2965872
- DOI: 10.1038/sj.bjc.6605864
A clinical risk score to predict 3-, 5- and 10-year survival in patients undergoing surgery for Dukes B colorectal cancer
Abstract
Background: The prognosis of patients with Dukes stage B colorectal cancer is unpredictable and there is continuing interest in simply and reliably identifying patients at high risk of developing recurrence and dying of their disease. The aim of this study was to devise a clinical risk score to predict 3-, 5- and 10-year survival in patients undergoing surgery for Dukes stage B colorectal cancer.
Methods: A total of 1350 patients who underwent surgery for Dukes stage B colorectal cancer between 1991 and 1994 in 11 hospitals in Scotland were included in the analysis.
Results: On follow-up, 926 patients died of whom 479 died of their cancer. At 10 years, cancer-specific survival was 61% and overall survival was 38%. On multivariate analysis, age ≥75 (hazard ratio (HR) 1.45, 95% confidence interval (CI) 1.15-1.82, P=0.001), emergency presentation (HR 1.59, 95% CI 1.27-1.99, P<0.001) and anastomotic leak (HR 2.17, 95% CI 1.24-3.78, P<0.01) were independently associated with cancer-specific survival in colon cancer. On multivariate analysis, only age ≥75 (HR 1.58, 95% CI 1.14-2.18, P<0.01) was associated with cancer-specific survival in rectal cancer. Age, presentation and anastomotic leak hazards could be simply added to form a clinical risk score from 0 to 2 in colon cancer. In patients with Dukes B stage colon cancer, the cancer-specific survival at 5 years for patients with a cumulative score 0 was 81%, 1 was 67% and 2 was 63%. The cancer-specific survival rate at 10 years for patients with a clinical risk score of 0 was 72%, 1 was 58% and 2 was 53%.
Conclusion: The results of this study, in a mature cohort, introduce a new simple clinical risk score for patients undergoing surgery for Dukes B colon cancer. This provides a solid foundation for the examination of the impact of additional factors and treatment on prediction of 3-, 5- and 10-year cancer-specific survival.
Figures
Similar articles
-
The impact of young age on cancer-specific and non-cancer-related survival after surgery for colorectal cancer: 10-year follow-up.Br J Cancer. 2009 Aug 18;101(4):557-60. doi: 10.1038/sj.bjc.6605222. Br J Cancer. 2009. PMID: 19672260 Free PMC article.
-
The impact of old age on cancer-specific and non-cancer-related survival following elective potentially curative surgery for Dukes A/B colorectal cancer.Br J Cancer. 2008 Oct 7;99(7):1046-9. doi: 10.1038/sj.bjc.6604669. Epub 2008 Sep 16. Br J Cancer. 2008. PMID: 18797465 Free PMC article.
-
Clinical significance of circulating tumor cells, including cancer stem-like cells, in peripheral blood for recurrence and prognosis in patients with Dukes' stage B and C colorectal cancer.J Clin Oncol. 2011 Apr 20;29(12):1547-55. doi: 10.1200/JCO.2010.30.5151. Epub 2011 Mar 21. J Clin Oncol. 2011. PMID: 21422427
-
Lymph node recovery from colorectal tumor specimens: recommendation for a minimum number of lymph nodes to be examined.World J Surg. 2002 Mar;26(3):384-9. doi: 10.1007/s00268-001-0236-8. Epub 2002 Jan 15. World J Surg. 2002. PMID: 11865379
-
Differential Impact of Anastomotic Leak in Patients With Stage IV Colonic or Rectal Cancer: A Nationwide Cohort Study.Dis Colon Rectum. 2017 May;60(5):497-507. doi: 10.1097/DCR.0000000000000761. Dis Colon Rectum. 2017. PMID: 28383449
Cited by
-
Improving the outcomes in oncological colorectal surgery.World J Gastroenterol. 2014 Sep 21;20(35):12445-57. doi: 10.3748/wjg.v20.i35.12445. World J Gastroenterol. 2014. PMID: 25253944 Free PMC article. Review.
-
Clinical value of prognosis gene expression signatures in colorectal cancer: a systematic review.PLoS One. 2012;7(11):e48877. doi: 10.1371/journal.pone.0048877. Epub 2012 Nov 7. PLoS One. 2012. PMID: 23145004 Free PMC article.
-
Evolving notions on immune response in colorectal cancer and their implications for biomarker development.Inflamm Res. 2018 May;67(5):375-389. doi: 10.1007/s00011-017-1128-1. Epub 2018 Jan 10. Inflamm Res. 2018. PMID: 29322204 Review.
-
Validation of a modified clinical risk score to predict cancer-specific survival for stage II colon cancer.Cancer Med. 2015 Jan;4(1):84-9. doi: 10.1002/cam4.352. Epub 2014 Dec 8. Cancer Med. 2015. PMID: 25487740 Free PMC article.
-
Long noncoding RNA profiles identify five distinct molecular subtypes of colorectal cancer with clinical relevance.Mol Oncol. 2014 Dec;8(8):1393-403. doi: 10.1016/j.molonc.2014.05.010. Epub 2014 Jun 2. Mol Oncol. 2014. PMID: 24954858 Free PMC article.
References
-
- Benson III AB, Schrag D, Somerfield MR, Cohen AM, Figueredo AT, Flynn PJ, Krzyzanowska MK, Maroun J, McAllister P, Van Cutsem E, Brouwers M, Charette M, Haller DG (2004) American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol 22: 3408–3419 - PubMed
-
- Benson III AB (2007) New approaches to assessing and treating early-stage colon and rectal cancers: cooperative group strategies for assessing optimal approaches in early-stage disease. Clin Cancer Res 13(22 Part 2): 6913s–69120s, - PubMed
-
- Carstairs V, Morris R (1991) Deprivation and Health in Scotland. Aberdeen University Press: Aberdeen
-
- Cascinu S, Georgoulias V, Kerr D, Maughan T, Labianca R, Ychou M (2003) Colorectal cancer in the adjuvant setting: perspectives on treatment and the role of prognostic factors. Ann Oncol 14(Suppl 2): ii25–ii29 - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical